Premium Phosphosite-Specific 7TM Antibodies
Novel Tools for Your GPCR Research
Select Your Country of Delivery below

LPA5 Receptor Antibodies

Close filters
No results were found for the filter!
NEW
Validation of the Lysophosphatidic Acid Receptor 5 in transfected HEK293 cells
LPA5 (non-phospho), Lysophosphatidic Acid...
The non-phospho-LPA5 receptor antibody is directed against the distal end of the carboxyl-terminal tail of human LPA5. It can be used to detect total LPA5 receptors in Western blots independent of phosphorylation. The LPA5 antibody can...
$ 400.00 *
Details

The lysophosphatidic acid receptor 5 (LPA₅), encoded by the LPAR5 gene, is a class A G protein–coupled receptor (GPCR) that binds the bioactive lipid lysophosphatidic acid (LPA) and mediates distinct cellular responses compared with LPA₁–₄ receptors. LPA₅ couples primarily to G12/13 and Gq/11 proteins, leading to activation of RhoA, phospholipase C (PLC), intracellular calcium mobilization, and ERK/MAPK signaling, which regulate cell motility, cytoskeletal organization, and proliferation. It is expressed in a variety of tissues, including the gastrointestinal tract, immune cells, brain, and endothelial cells, suggesting roles in both immune regulation and tissue homeostasis. Functionally, LPA₅ has been implicated in platelet activation, neuropathic pain, immune cell chemotaxis, and the regulation of intestinal barrier integrity. In cancer, LPA₅ signaling can influence tumor cell migration and invasion, although its effects are sometimes context-dependent and can differ from other LPA receptors. Pharmacological studies using selective agonists and antagonists have revealed its role as a key lipid-sensing receptor mediating both pro-migratory and inhibitory signals depending on cell type. Additionally, LPA₅ contributes to inflammatory responses by modulating cytokine release and leukocyte function. Overall, LPA₅ serves as a versatile modulator of cell signaling, linking lipid mediators to immune, vascular, and neuronal processes, and represents a potential therapeutic target in pain, inflammation, and cancer. For more information on LPA5 pharmacology please refer to the IUPHAR database. For further reading refer to:

Chun J, Hla T, Lynch KR, Spiegel S, Moolenaar WH. International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid receptor nomenclature. Pharmacol Rev. 2010 Dec;62(4):579-87. doi: 10.1124/pr.110.003111. PMID: 21079037; PMCID: PMC2993255.

Kihara Y, Maceyka M, Spiegel S, Chun J. Lysophospholipid receptor nomenclature review: IUPHAR Review 8. Br J Pharmacol. 2014 Aug;171(15):3575-94. doi: 10.1111/bph.12678. Epub 2014 Jul 12. PMID: 24602016; PMCID: PMC4128058.

Blaho V, Chun J, Herr D, Jones D, Jonnalagadda D, Kihara Y. Lysophospholipid (S1P) receptors in GtoPdb v.2023.1. IUPHAR/BPS Guide to Pharmacology CITE. 2023; 2023(1).

The lysophosphatidic acid receptor 5 (LPA₅), encoded by the LPAR5 gene, is a class A G protein–coupled receptor (GPCR) that binds the bioactive lipid lysophosphatidic acid (LPA) and mediates... read more »
Close window
LPA5 Receptor Antibodies

The lysophosphatidic acid receptor 5 (LPA₅), encoded by the LPAR5 gene, is a class A G protein–coupled receptor (GPCR) that binds the bioactive lipid lysophosphatidic acid (LPA) and mediates distinct cellular responses compared with LPA₁–₄ receptors. LPA₅ couples primarily to G12/13 and Gq/11 proteins, leading to activation of RhoA, phospholipase C (PLC), intracellular calcium mobilization, and ERK/MAPK signaling, which regulate cell motility, cytoskeletal organization, and proliferation. It is expressed in a variety of tissues, including the gastrointestinal tract, immune cells, brain, and endothelial cells, suggesting roles in both immune regulation and tissue homeostasis. Functionally, LPA₅ has been implicated in platelet activation, neuropathic pain, immune cell chemotaxis, and the regulation of intestinal barrier integrity. In cancer, LPA₅ signaling can influence tumor cell migration and invasion, although its effects are sometimes context-dependent and can differ from other LPA receptors. Pharmacological studies using selective agonists and antagonists have revealed its role as a key lipid-sensing receptor mediating both pro-migratory and inhibitory signals depending on cell type. Additionally, LPA₅ contributes to inflammatory responses by modulating cytokine release and leukocyte function. Overall, LPA₅ serves as a versatile modulator of cell signaling, linking lipid mediators to immune, vascular, and neuronal processes, and represents a potential therapeutic target in pain, inflammation, and cancer. For more information on LPA5 pharmacology please refer to the IUPHAR database. For further reading refer to:

Chun J, Hla T, Lynch KR, Spiegel S, Moolenaar WH. International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid receptor nomenclature. Pharmacol Rev. 2010 Dec;62(4):579-87. doi: 10.1124/pr.110.003111. PMID: 21079037; PMCID: PMC2993255.

Kihara Y, Maceyka M, Spiegel S, Chun J. Lysophospholipid receptor nomenclature review: IUPHAR Review 8. Br J Pharmacol. 2014 Aug;171(15):3575-94. doi: 10.1111/bph.12678. Epub 2014 Jul 12. PMID: 24602016; PMCID: PMC4128058.

Blaho V, Chun J, Herr D, Jones D, Jonnalagadda D, Kihara Y. Lysophospholipid (S1P) receptors in GtoPdb v.2023.1. IUPHAR/BPS Guide to Pharmacology CITE. 2023; 2023(1).

Recently viewed